United Therapeutics (NASDAQ:UTHR) is a biotechnology company focused on the development and commercialization of innovative therapies to address life-threatening conditions. Founded in 1996 by Martine Rothblatt and headquartered in Silver Spring, Maryland, the company has established itself as a leader in pulmonary arterial hypertension (PAH) treatment. From its early days, United Therapeutics set out to expand treatment options, improve delivery methods and pursue transformative approaches to extend and enhance patient lives.
The company’s core product portfolio centers on FDA-approved therapies for PAH, including intravenous and subcutaneous formulations of treprostinil marketed under the brand name Remodulin, an inhaled version known as Tyvaso, an oral extended-release tablet called Orenitram, and the oral phosphodiesterase-5 inhibitor Adcirca. United Therapeutics has also developed Tyvaso DPI, a dry powder inhalation form of treprostinil designed to improve patient convenience and adherence. These treatments help relax pulmonary blood vessels, reduce symptoms and slow disease progression for patients with high pulmonary artery pressure.
Beyond PAH, United Therapeutics has diversified its pipeline into oncology and novel transplant technologies. The company is investigating immuno-oncology approaches and cell-based therapies aimed at solid tumors, while its organ manufacturing division is pioneering xenotransplantation. This program includes genetic engineering of porcine organs to address shortages in human organ transplants, with ongoing research partnerships at leading academic institutions and surgical centers. United Therapeutics’ long-term vision encompasses regenerative medicine solutions that could revolutionize care for end-stage organ failure.
United Therapeutics maintains a global presence with operations in North America, Europe and Asia. The company operates research and manufacturing facilities in the United States, including major production sites in North Carolina, and collaborates with regulatory authorities and healthcare providers worldwide. Under the leadership of founder and CEO Martine Rothblatt, United Therapeutics continues to invest in next-generation drug delivery platforms, pipeline expansion and strategic partnerships to bring novel therapies from concept to clinic, fulfilling its mission to deliver life-saving medicines to patients facing critical health challenges.
